Late Phase Reactions
Abstract:Our current understanding of LPR has evolved over the past 10–12 years, and there are still many areas where our information is still incomplete and cannot provide solid support for several of the hypotheses presented herein. Each suggestion presented is testable, however, and answers to many of the questions raised should eventually be available. The hypotheses presented provide a framework for understanding how airway inflammation contributes to airway reactivity and how certain irritant exposures can cause delayed-onset asthma. More importantly, they provide a rationale for the use of many of the specific drugs used to treat allergies and asthma. Indeed, if LPR and airway inflammation are as important in asthma (and other allergic diseases) as these hypotheses suggest, the use of agents specifically designed to prevent or treat LPR should increase.
Thus, mast cell stabilizing compounds such as cromoglycate, ketotifen, and tranilast and anti-inflammatory agents like GCS might be viewed as specific therapy for asthma (and other allergic diseases), while bronchodilators (like antihistamines, decongestants and antipruritic drugs in other allergic diseases) might be considered as supportive agents. These concepts therefore suggest the early and aggressive use of specific agents in asthma while employing supportive drugs to help maintain lung function.
Document Type: Research Article
Publication date: May 1, 1986
More about this publication?
- Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.
The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
- Editorial Board
- Information for Authors
- Submit a Paper
- Information for Advertisers
- Reprint Requests
- Ingenta Connect is not responsible for the content or availability of external websites